» PARP Inhibitors Poised to Change Prostate Cancer Standard of Care - Targeted Oncology
25/02/20 16:39 from BRCA - Google News
PARP Inhibitors Poised to Change Prostate Cancer Standard of Care Targeted Oncology
» Association of BRCA Mutantations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines. - Physician's Weekly
25/02/20 12:44 from BRCA - Google News
Association of BRCA Mutantations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines. Physician's Weekly
» FDA Accepts GSK's sNDA for Zejula as a First-Line Maintenance Treatment in Ovarian Cancer - BioSpace
25/02/20 12:34 from BRCA - Google News
FDA Accepts GSK's sNDA for Zejula as a First-Line Maintenance Treatment in Ovarian Cancer BioSpace
» Talazoparib active, safe among subset of men with metastatic prostate cancer - Healio
25/02/20 10:32 from BRCA - Google News
Talazoparib active, safe among subset of men with metastatic prostate cancer Healio
» Epic EMR Users Begin Integrating Genomics Data for Clinical Decision Support - GenomeWeb
25/02/20 10:30 from BRCA - Google News
Epic EMR Users Begin Integrating Genomics Data for Clinical Decision Support GenomeWeb
» Epic EMR Users Begin Integrating Genomics Data for Clinical Decision Support - Precision Oncology News
25/02/20 10:30 from BRCA - Google News
Epic EMR Users Begin Integrating Genomics Data for Clinical Decision Support Precision Oncology News
» Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat - Yahoo Finance
25/02/20 10:12 from BRCA - Google News
Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat Yahoo Finance
» Rohingya Diaspora: Transnational Identity in the Digital Age - The Diplomat
25/02/20 09:59 from BRCA - Google News
Rohingya Diaspora: Transnational Identity in the Digital Age The Diplomat
» FDA Accepts Niraparib Application for Frontline Maintenance Ovarian Cancer Treatment - www.oncnursingnews.com/
25/02/20 09:34 from BRCA - Google News
FDA Accepts Niraparib Application for Frontline Maintenance Ovarian Cancer Treatment www.oncnursingnews.com/
» FDA accepts review to broaden GSK's Zejula label - PMLiVE
25/02/20 06:11 from BRCA - Google News
FDA accepts review to broaden GSK's Zejula label PMLiVE